BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 16437378)

  • 1. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
    Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
    Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors.
    McCluggage WG; Strand K; Abdulkadir A
    Int J Gynecol Cancer; 2002; 12(1):62-5. PubMed ID: 11860537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
    Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
    Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
    Tan Y; Sinniah R; Bay BH; Singh G
    J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory role of prohibitin in human ovarian epithelial cancer.
    Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
    Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
    Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
    Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer.
    Ahmed N; Riley C; Rice GE; Quinn MA; Baker MS
    J Histochem Cytochem; 2002 Oct; 50(10):1371-80. PubMed ID: 12364570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
    Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
    Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
    Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
    Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical localization of metallothionein and p53 protein in pancreatic serous cystadenomas.
    Sliwińska-Mossoń M; Milnerowicz H; Rabczyński J; Milnerowicz S
    Arch Immunol Ther Exp (Warsz); 2009; 57(4):295-301. PubMed ID: 19578815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
    Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
    J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and overt carcinomas.
    Darai E; Walker-Combrouze F; Fauconnier A; Madelenat P; Potet F; Scoazec JY
    Histopathology; 1998 Feb; 32(2):151-9. PubMed ID: 9543672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
    Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
    Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cell regulatory proteins in ovarian borderline tumors.
    van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
    Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p63 expression in epithelial ovarian tumors.
    Poli Neto OB; Candido Dos Reis FJ; Zambelli Ramalho LN; Nogueira AA; de Andrade JM
    Int J Gynecol Cancer; 2006; 16(1):152-5. PubMed ID: 16445626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
    Kamiński K; Putowski L; Oleszczuk J
    Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.